Binciken Nasara Ya Nuna Tsaro Da Ingancin Maganin CAR-T Wajen Magance Cututtukan B-Cell
Wani bincike da aka yi kwanan nan karkashin jagorancin Dr. Zhi-tao Ying daga Asibitin Cutar Daji na Jami'ar Peking ya nuna sakamako mai kyau a cikin maganin cututtukan jini na B-cell da suka sake dawowa da kuma suka yi tsauri ta amfani da sabon maganin ƙwayoyin cuta na chimeric antigen receptor T (CAR-T), IM19. An buga a cikin Mujallar Sin game da Sabbin Magunguna, binciken ya nuna muhimmancin tasirin IM19 ga marasa lafiya waɗanda suka gaji da zaɓuɓɓukan magani na gargajiya.
Binciken ya shafi marasa lafiya 12, waɗanda aka raba su daidai gwargwado tsakanin waɗanda ke fama da ƙwayoyin B. Lymphoma na NonHodgkin (NHL) da kuma cutar sankarar jini ta B-cell lymphoblastic leukemia (B-ALL). An yi wa marasa lafiya magani da allurai daban-daban na ƙwayoyin CAR-T na IM19, waɗanda aka saka bayan wani tsari na sharaɗi da ya haɗa da fludarabine da cyclophosphamide. Babban ƙarshen binciken ya haɗa da kimanta yawan amsawar gabaɗaya, juriyar ƙwayoyin CAR-T, sakin cytokine, da kuma sa ido kan abubuwan da suka faru marasa kyau.
(Hoto yana nuna murmurewa daga marasa lafiya na NHL da B-ALL)
Abin mamaki, 11 daga cikin marasa lafiya 12 sun sami cikakkiyar sassauci, tare da yaduwar IM19 a cikin jinin su. Maganin ya haifar da ƙaruwar cytokines kamar interleukin-6 da interleukin-10, wanda ke nuna ƙarfin amsawar garkuwar jiki. Abu mafi mahimmanci, babu ɗaya daga cikin marasa lafiyar da ya taɓa fuskantar mummunan yanayin sakin cytokine ko kuma cutar CAR-T da ke da alaƙa da ƙwayoyin cuta, wanda ke nuna kyakkyawan yanayin lafiyar maganin.
Wata tawagar hadin gwiwa daga Asibitin Cutar Daji na Jami'ar Peking, Asibitin Hebei Yanda Lu Daopei, da kuma Kamfanin Magunguna na Beijing Immunochina Pharmaceuticals ce ta gudanar da binciken. Dr. Ying, babban marubucin, ya kware a gano da kuma magance cutar sankarar lymphocyte mai tsanani, yayin da Dr. Jun Zhu, marubucin da ya yi magana da shi, kwararren masani ne a wannan fanni. Wannan binciken ya samu goyon baya daga wasu manyan tallafi, ciki har da Gidauniyar Kimiyyar Halitta ta Kasa ta China da Gidauniyar Kimiyyar Halitta ta Beijing.
Wannan bincike mai zurfi ya bayar da shaida mai ƙarfi cewa maganin IM19 CAR-T ba wai kawai yana da tasiri ba har ma yana da aminci ga marasa lafiya da ke fama da ƙalubalen ƙwayoyin B. Yana share fagen bincike na gaba da kuma yiwuwar amfani da shi a asibiti, yana ba da sabuwar bege ga marasa lafiya da ke da ƙarancin zaɓuɓɓukan magani.